Educational only. Not medical or legal advice. This site summarizes public U.S. government statements as of October 22, 2026. It does not sell, recommend or endorse any product, and it does not give dosing information. Talk to a licensed clinician about any medicine, and check the linked FDA pages for the latest version.
Each row summarizes what the linked FDA page says. Where FDA's page gives a date, we show it; otherwise we show the date we last checked the page. The FDA page controls if anything differs.
| Compound | FDA category / status | Date | Source |
|---|---|---|---|
| Semaglutide injection | FDA-approved (e.g., Ozempic, Wegovy); FDA shortage resolved | Feb 21, 2025 | FDA Declaratory Order |
| Tirzepatide injection | FDA shortage resolved (re-affirmed) | Dec 19, 2024 | FDA |
| Semaglutide & tirzepatide | Not on 503B bulks list or FDA drug shortage list | Apr 1, 2026 (FDA update) | FDA |
| Semaglutide sodium / acetate (salt forms) | FDA: not aware of a lawful basis for use in compounding | Checked Oct 22, 2026 | FDA |
| Retatrutide | Cannot be used in compounding under federal law; not FDA-approved | Checked Oct 22, 2026 | FDA |
| Cagrilintide | Cannot be used in compounding under federal law; not FDA-approved | Checked Oct 22, 2026 | FDA |
| GHRP-2 (injectable and nasal) | 503A bulks category 2 (significant safety risks) — 503B | Sep 29, 2023 | FDA |
| GHRP-6 | 503A bulks category 2 (significant safety risks) — 503B | Sep 29, 2023 | FDA |
| Ibutamoren mesylate | 503A bulks category 2 (significant safety risks) — 503A and 503B | 503A Sep 29, 2023; 503B Dec 29, 2022 | FDA |
| Ipamorelin acetate | 503A bulks category 2 (significant safety risks) — 503B | Sep 29, 2023 | FDA |
| Kisspeptin-10 | 503A bulks category 2 (significant safety risks) — 503A | Sep 29, 2023 | FDA |
| AOD-9604 | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| BPC-157 | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| Cathelicidin LL-37 | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| CJC-1295 | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| Dihexa acetate | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| Emideltide (DSIP) | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| Epitalon | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| GHK-Cu (injectable routes) | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| Ipamorelin acetate | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| KPV | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| PEG-MGF | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| Melanotan II | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| MOTs-C | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| Selank acetate (TP-7) | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| Semax (heptapeptide) | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| Thymosin-alpha 1 | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
| Thymosin beta-4 fragment (TB-500) | Nominated; previously category 2; nomination withdrawn (not approved, not on 503A bulks list) | Checked Oct 22, 2026 | FDA |
Cite this page: "FDA peptide status tracker," Peptide FDA Guide, as of October 22, 2026. Get an email when it changes.